https://www.fqhctalent.com Intelligence items mentioning Tarzana Treatment Centers (Los Angeles). Updated whenever we publish new intel about this FQHC. en-us Mon, 27 Jul 2026 19:59:52 GMT https://www.fqhctalent.com/intel/fda-first-medical-ai-was-diabetic-retinopathy-2018 Strategic context: vision is the bow wave of clinical AI adoption — not radiology, not pathology, not ambient documentation. The FIRST FDA De Novo authorized autonomous AI in the entire history of US medicine was IDx-DR (now LumineticsCore from Digital Diagnostics) in April 2018, for diabetic retinopathy detection in primary care. 87.2% sensitivity / 90.7% specificity. Two more autonomous AI systems followed: EyeArt (Eyenuk, 2020 — 96% sens / 88% spec for mtmDR), and AEYE-DS (AEYE Health, 2022 — 93% / 91.4%, expanded 2024 for handheld portable). Plus SCANLY Home OCT (Notal Vision, May 2024) — first FDA-authorized patient-self-operated home OCT. Cahaba Medical Care (AL FQHC) deployment data: AI identified previously-missed DR in >1-in-4 patients screened. CA documented FQHC adopters: Tarzana Treatment Centers (LumineticsCore), San Ysidro Health (EyeArt RCT). Primary source: FDA — https://www.accessdata.fda.gov/cdrh_docs/reviews/DEN180001.pdf Wed, 11 Apr 2018 00:00:00 GMT https://www.fqhctalent.com/intel/fda-first-medical-ai-was-diabetic-retinopathy-2018 change-management FDA